Phase 3Active, not recruiting
Oral Pyridoxal 5'-Phosphate for the Treatment of Patients With PNPO Deficiency (MEND-PNPO)
Study of Pyridoxal 5'-Phosphate for the Treatment of Patients With PNPO Deficiency
- Sponsor
- Medicure (Industry)
- Enrollment
- 15 planned
- Conditions
- Pyridox(am)Ine 5'-Phosphate Oxidase Deficiency
- Interventions
- Pyridoxal Phosphate
- Ages
- children, adults, older adults
- Registry
- NCT04706013
Full record on ClinicalTrials.gov
From the registry
The proposed clinical study is intended to evaluate oral P5P for the treatment of patients confirmed to have Pyridox(am)ine 5'-Phosphate Oxidase (PNPO) deficiency via genetic analysis. There is an unmet clinical need for pharmaceutical grade P5P, as to date none has been made commercially available. Patients will receive pharmaceutical grade P5P according to their normal oral P5P dosing regimen, as previously established by their physicians.
Primary outcomes
- Overall survival time (time to death), including incidence of death at 12 months
History
Primary completion expected
Last registry update
Started
Registered